Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
(Date:5/20/2013)... PA (PRWEB) May 20, 2013 Interventional ... Allegheny General Hospital (AGH) Cardiovascular Institute have ... coronary artery disease (CAD) over the past ... such as balloon angioplasty and coronary artery stent implantation. ... once again play a prominent role in the study ...
(Date:5/20/2013)... 20, 2013 Kitware, a leader in ... that enables the exploration of hospital costs across ... response to the recent release of “Medicare Provider Charge ... 100 most-billed procedures from the Centers for Medicare & ... similar procedures at hospitals across the country has sparked ...
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), a ... announced that the company's YouTube channel on SEO ... on YouTube. The company uses YouTube as a way ... training for small businesses with much success. , "I ... helpful for their SEO strategies", explained Jason McDonald, director ...
Breaking Biology Technology:BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Kitware Enables Interactive Exploration of CMS Medicare Data 2YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2
... December 3 On,November 28, Essilor cancelled 1,600,000 shares, ... dilutive impact of Oceane bond conversions and,the Company,s stock ... These latest cancellations concerned shares acquired under the 6.9,million ... on July,15, 2008 to offset the dilutive impact of ...
... Dec. 2 Transgenomic,Inc. (OTC Bulletin Board: ... Board: PWRM) today announced that Transgenomic has ... rights for Power3 Medical,s Neurodegenerative,Biomarkers, which include ... disease. Transgenomic plans to offer NuroPro(R) ...
... 2 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company ... the areas of women,s health and,cancer, announced that Isaac Cohen, Chairman ... at the 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. ... at,the New York Palace Hotel in New York City. , ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ... develop the semantic components and ontologies shared by the ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... birth to develop the ability to determine sunrise and ... of Chicago shows. The research sheds new light ... behaviors, according to Brian Prendergast, associate professor in psychology ... paper published April 27 in the journal PLoS One. ...
... to investigate such things as how Pacific Northwest forests ... by pests and diseases is being pruned back to ... located in a 500-year-old forest near Stevenson in southwest ... Washington, the Forest Service,s Pacific Northwest Research Station and ...
... An international team of scientists, led by researchers at ... have developed a new method for discerning the functions ... functional networks that reveal how gene products interact to ... in the April 29 issue of the journal Cell. ...
Cached Biology News:From the beginning, the brain knows the difference between night and day 2Era of canopy crane ending; certain research and education activities remain 2Era of canopy crane ending; certain research and education activities remain 3As the worm turns, its secrets are revealed 2
...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
RECK (F-20)...
... polyclonal to Peroxiredoxin 1 Peroxiredoxin ... whose mammalian members have been known ... and apoptosis. Many isoforms (about 50 ... amino acid sequence homology, particularly amino-terminal ...
Biology Products: